Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients
2014 | conference abstract. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients
Herrlinger, U.; Schaefer, N.; Steinbach, J. P.; Weyerbrock, A.; Hau, P.; Goldbrunner, R. & Friedrich, F. et al. (2014)
Journal of Clinical Oncology, 32(15) 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Chicago, IL.
Alexandria: Amer Soc Clinical Oncology.
Documents & Media
Details
- Authors
- Herrlinger, Ulrich; Schaefer, Nildas; Steinbach, Joachim Peter; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Friedrich, Franziska; Rohde, Veit; Ringel, Florian; Braun, Christian; Kohnen, Ralf; Leutgeb, Barbara; Belka, Claus; Urbach, Horst; Stummer, Walter; Gies, Martin
- Issue Date
- 2014
- Status
- published
- Publisher
- Amer Soc Clinical Oncology
- Journal
- Journal of Clinical Oncology
- Conference
- 50th Annual Meeting of the American-Society-of-Clinical-Oncology
- Conference Place
- Chicago, IL
- ISSN
- 1527-7755; 0732-183X
